Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen K Doberstein

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Drug Discovery Today|July 19, 2006
HTS technologies in biopharmaceutical discoveryGe Wu, Stephen K Doberstein
Plos One|July 6, 2017
Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapyDeborah Charych, Samira Khalili, Vidula Dixit, et al.
Pain Medicine (Malden, Mass.)|March 10, 2020
Measuring Opioid Withdrawal in a Phase 3 Study of a New Analgesic, NKTR-181 (Oxycodegol), in Patients with Moderate to Severe Chronic Low Back PainJack E Henningfield, Jeffrey Gudin, Richard Rauck, et al.
Pain|February 13, 2019
SUMMIT-07: a randomized trial of NKTR-181, a new molecular entity, full mu-opioid receptor agonist for chronic low-back painJohn Markman, Jeffrey Gudin, Richard Rauck, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 21, 2007
Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infectionJonathan Zalevsky, Thomas Secher, Sergei A Ezhevsky, et al.
Pain Medicine (Malden, Mass.)|July 31, 2019
Long-term Safety and Tolerability of NKTR-181 in Patients with Moderate to Severe Chronic Low Back Pain or Chronic Noncancer Pain: A Phase 3 Multicenter, Open-Label, 52-Week Study (SUMMIT-08 LTS)Jeffrey Gudin, Richard Rauck, Charles Argoff, et al.
Pain Medicine (Malden, Mass.)|September 26, 2019
Human Abuse Potential of Oral NKTR-181 in Recreational Opioid Users: A Randomized, Double-Blind, Crossover StudyXue Ge, Jack E Henningfield, Suresh Siddhanti, et al.
Current Medical Research and Opinion|April 2, 2019
Assessment of potentially abuse-related events in two phase 3 studies of NKTR-181, a novel opioid analgesic, using the MADDERS® system (Misuse, Abuse, and Diversion Drug Event Reporting System)Ryan K Lanier, Jack E Henningfield, Jeffrey Gudin, et al.
Science (New York, N.Y.)|May 10, 2008
Discovery of a cytokine and its receptor by functional screening of the extracellular proteomeHaishan Lin, Ernestine Lee, Kevin Hestir, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 6, 2017
NKTR-181: A Novel Mu-Opioid Analgesic with Inherently Low Abuse PotentialTakahiro Miyazaki, Irene Y Choi, Werner Rubas, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Drug Discovery Today|July 19, 2006
HTS technologies in biopharmaceutical discoveryGe Wu, Stephen K Doberstein
Plos One|July 6, 2017
Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapyDeborah Charych, Samira Khalili, Vidula Dixit, et al.
Pain Medicine (Malden, Mass.)|March 10, 2020
Measuring Opioid Withdrawal in a Phase 3 Study of a New Analgesic, NKTR-181 (Oxycodegol), in Patients with Moderate to Severe Chronic Low Back PainJack E Henningfield, Jeffrey Gudin, Richard Rauck, et al.
Pain|February 13, 2019
SUMMIT-07: a randomized trial of NKTR-181, a new molecular entity, full mu-opioid receptor agonist for chronic low-back painJohn Markman, Jeffrey Gudin, Richard Rauck, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 21, 2007
Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infectionJonathan Zalevsky, Thomas Secher, Sergei A Ezhevsky, et al.
Pain Medicine (Malden, Mass.)|July 31, 2019
Long-term Safety and Tolerability of NKTR-181 in Patients with Moderate to Severe Chronic Low Back Pain or Chronic Noncancer Pain: A Phase 3 Multicenter, Open-Label, 52-Week Study (SUMMIT-08 LTS)Jeffrey Gudin, Richard Rauck, Charles Argoff, et al.
Pain Medicine (Malden, Mass.)|September 26, 2019
Human Abuse Potential of Oral NKTR-181 in Recreational Opioid Users: A Randomized, Double-Blind, Crossover StudyXue Ge, Jack E Henningfield, Suresh Siddhanti, et al.
Current Medical Research and Opinion|April 2, 2019
Assessment of potentially abuse-related events in two phase 3 studies of NKTR-181, a novel opioid analgesic, using the MADDERS® system (Misuse, Abuse, and Diversion Drug Event Reporting System)Ryan K Lanier, Jack E Henningfield, Jeffrey Gudin, et al.
Science (New York, N.Y.)|May 10, 2008
Discovery of a cytokine and its receptor by functional screening of the extracellular proteomeHaishan Lin, Ernestine Lee, Kevin Hestir, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 6, 2017
NKTR-181: A Novel Mu-Opioid Analgesic with Inherently Low Abuse PotentialTakahiro Miyazaki, Irene Y Choi, Werner Rubas, et al.
Pageof 2